Background: Normal tissue toxicity to the CNS is an inevitable consequence of a successful radiotherapy of brain tumors or cancer metastases to the CNS.
Introduction
Exposure of the central nervous system to ionizing radiation results in normal tissue toxicity 1 . With survival times for cancer patients steadily increasing over the past decades 2 , more and more patients are now at risk of experiencing late effects of radiotherapy. Patients receiving cranial irradiation -and among those in particular pediatric patients-are facing a decline in cognitive function later in life [3] [4] [5] . The underlying mechanisms include neuroinflammation, diminished neuronal connectivity and demyelination 1 . Earlier studies by Limoli and colleagues demonstrated that the functional consequences of brain irradiation can be mitigated by injection of neural stem cells into the brain and that newly derived neurons from this stem cell population integrate into the circuitry of the adult brain 6 . Furthermore, that activation of microglia is a critical factor for radiationinduced neuroinflammation, which ultimately leads to cognitive decline. These data indicated that mitigating radiation effects in the intrinsic neural stem/progenitor cell population and microglia cells could be exploited in the radiotherapy setting to prevent radiation-induced cognitive decline.
We previously reported that 1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine (compound #5) prevents the acute radiation syndrome in mice by activating the hedgehog signaling pathway 7, 8 . In this study we tested if compound #5 has an effect on the neural stem/progenitor cell population. Our data show that compound #5 when given after cranial irradiation preserves the neural stem/progenitor cell population, inhibits microglia activation, mitigates radiation-induced neuroinflammation and prevents radiation-induced cognitive impairment in mice.
Materials and Methods

Animals
Nestin-EGFP mice were a kind gift from Dr. Grigori Enikolopov, Cold Spring Harbor Laboratory 9 . C3Hf/Sed/Kam were originally obtained from the MD Anderson Cancer Center. All experiments were performed in accordance to all local and national guidelines for the care of animals.
For orthotopic tumor grafting 2x10 5 GL261-Luciferase cells were implanted into the right striatum of the brains of female C57Bl/6 mice using a stereotactic frame (Kopf Instruments, Tujunga, CA) and a nano-injector pump (Stoelting, Wood Dale, IL). Injection coordinates were 0.5 mm anterior and 2.25 mm lateral to the bregma, at a depth of 3.5 mm from the surface of the brain. Tumors were grown for 7 days after which successful grafting was confirmed by bioluminescence imaging.
Cell culture
For neural stem cell cultures the entire brains of the newborn Nestin-GFP mice were harvested, minced using a scalpel and transferred to a fresh Eppendorf tube with 1 ml of 0.05 % trypsin-EDTA (Thermo Fisher Scientific, # 25300-054), mixed and incubated at 37°C for 7 minutes. The trypsin was inhibited by adding 1 ml of trypsin inhibitor (Sigma-Aldrich, Cat# T6522). The tissue was centrifuged at 110 x g for 5 minutes and the supernatant was discarded. The tissue was resuspended in 200 µl of NeuroCult (Stem Cell Technologies, # 05702). The solution was mixed well to break down the tissue, diluted with 10 ml NeuroCult media and passed through a 70 µm cell strainer. The cell suspension was centrifuged at 110 x g for 5 minutes, the supernatant discarded and the cell pellet resuspended in 2 ml of ACK lysing buffer (Lonza, Cat# 10-548E). After centrifugation, cells from the final pellet were cultured in 1X complete NeuroCult media (45 ml of base NeuroCult media, 5 ml of supplement media, 1 µl of EGF, 20 µl of FGF, 3130 U/ml of heparin) under standard conditions (37° C, 5% CO 2 ) and labeled as Passage #1. Passage #2 cells were used for all experiments.
For microglia cell cultures EOC 20 cells (female; sourced from C3H/HeJ mice) were obtained from ATCC (Manassas, VA). Cells were maintained under standard conditions in DMEM media/10%FBS supplemented with 20% conditioned media from CSF-1-expressing LADMAC bone marrow cells (ATCC).
The primary human glioma cell lines were established at UCLA as described (Hemmati et al., PNAS 2003 10 ; Characteristics of specific gliomasphere lines can be found in Laks et al., Neuro-Oncology 2016 11 ). The GL261 murine glioma cell line was from obtained from Charles River Laboratories, Inc., Frederick, MD. GL261 cells were cultured in log-growth phase in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, penicillin and streptomycin. Primary HK-374 HK-157, HK-382 glioblastoma cells were propagated as gliomaspheres under serum-free conditions in ultra-low adhesion plates in DMEM/F12, supplemented with B27, EGF, bFGF and heparin as described previously 10-12 . All cells were grown in a humidified atmosphere at 37°C with 5% CO 2 . The unique identity of all patient-derived specimens was confirmed by DNA fingerprinting (Laragen, Culver City, CA). All lines were routinely tested for mycoplasma infection (MycoAlert, Lonza).
Quantitative Reverse Transcription-PCR
Total RNA was isolated using TRIZOL Reagent (Invitrogen). cDNA synthesis was carried out using the SuperScript Reverse Transcription IV (Invitrogen).
Quantitative PCR was performed in the QuantStudio 3 (Applied Biosystems, Thermo Fisher, Waltham, MA) using the PowerUp™ SYBR™ Green Master mix (Applied Biosystems, # A25742). C t for each gene was determined after normalization to HPRT (mouse) and GAPDH (human) and Δ Δ C t was calculated relative to the designated reference sample. Gene expression values were then set equal to 2 −ΔΔCt as described by the manufacturer of the kit (Applied Biosystems). All PCR primers were synthesized by Invitrogen and designed for the murine and human sequences of Ptch1, Ptch2, Gli1, Gli2, and the housekeeping genes HPRT and GAPDH (Supplement 1).
Il-6 Enzyme-Linked Immunosorbent Assays
Enzyme-linked immunosorbent assays (ELISA) were performed by following the manufacturer's instructions (mouse Il-6 Quantikine ELISA Kit, Fisher Scientific, # M6000B.). The absorbance was read at 450 nm (Spectramax M5, Molecular Devices, Sunnyvale, CA). A wavelength correction was performed by subtracting readings at 600 nm from the readings at 450 nm.
Irradiation
Neurosphere cultures were irradiated with 0, 2 or 4 Gy at room temperature using an experimental X-ray irradiator (Gulmay Medical Inc. Atlanta, GA) at a dose rate of 5.519 Gy/min. Control samples were sham-irradiated. The X-ray beam was operated at 300 kV and hardened using a 4 mm Be, a 3 mm Al, and a 1.5 mm Cu filter.
Eight-week-old mice were anaesthetized with isoflurane, cone beam computed tomography images were acquired, and individual treatment plans were calculated for each mouse using the SmART Plan software package.
Subsequently, the right hemisphere of the brain was irradiated with 4 Gy or 10 Gy using a single beam (for the in vivo experiments). For behavioral studies, the whole brain was irradiated with 10Gy using two opposing beams. The X-ray beam was operated at 225 kV.
NIST-traceable dosimetry on both X-ray machines was performed using a microionization chamber. Behavioral studies: Starting immediately after 10 Gy whole brain irradiation, mice received 5 daily sub-cutaneous injections of Compound #5 or DMSO/Cremophor EL.
In vitro drug treatment
In vitro assays with patient-derived glioblastoma specimens
For the assessment of self-renewal in vitro, HK-374, HK-157 and HK-382 cells were irradiated with 0, or 4 Gy. Three hours after irradiation, cells were treated with either DMSO or Compound #5. The media was supplemented with DMSO or Compound #5 every other day for two weeks. The number of spheres formed in each treatment groups was normalized against the non-irradiated control.
Brain dissociation
Five days after drug treatment, the brains of the mice were harvested and placed on the Acrylic Mouse Brain Slicer Matrix (Zivic Instruments, Cat# BSMAA001-1).
Coronal sections from 2 mm anterior to 2 mm posterior of the bregma were cut and the left hemisphere was separated from the right. The brain tissue was minced using a scalpel into very small pieces and the cells were isolated as mentioned in the above method section (Neural stem cell culture). The cells were then used for flow cytometric analysis to assess the percentage of Nestin-GFP + cells in different treatment groups or used to quantify self-renewal capacity in neurosphere formation assays.
Behavioral Testing
All of the behavioral experiments (Novel Obeject Recognition (NOR), Object in place (OIP), Fear Conditioning (FC)) were conducted in the Behavioral Testing Core (BTC) at UCLA. A detailed description is provided in Supplement 1.
Flow cytometry
Passage #2 neurospheres established from the brains of Nestin-GFP mice were harvested, dissociated into single cell suspension as described above.
Single cell suspensions were either subjected to FACS (Flow Cytometry Core, Terasaki, BD FACS ARIA) for GFP-high, -medium, and -low cell populations or analyzed for GFP expression using a MACSQuant Analyzer (Miltenyi Biosciences, Auburn, CA) and the FlowJo software package (v10, FlowJo, Ashland, OR).
Neurosphere-formation assay
In order to assess self-renewal capacity, passage #2 neurospheres from Nestin-GFP mice were trypsinized and plated in 1X complete NeuroCult media into 96-well non-treated plates, ranging from 1 to 1000 cells/well. Growth factors, EGF and bFGF, were added every 3 days, and the cells were allowed to form neurospheres for 14 days. The number of spheres formed per well was then counted and expressed as a percentage of the initial number of cells plated.
Immunohistochemistry
Brains were fixed in formalin, embedded in paraffin, and 4 µm coronal sections were stained for Ki67, GFAP and IBA-1 (Translational Pathology Core Laboratory at UCLA). Briefly, slides were placed in xylenes to remove paraffin, then a series of ethanol, washed in tap water, and incubated in 3% hydrogen peroxide/methanol for 10 minutes. After a wash in distilled water, the slides were 
Statistics
All statistical analyses were performed using the Graphpad Prism software package. Unless stated otherwise, results were derived from at least three animals per group. A p-value equal to or smaller than 0.05 in a student t-test or one-way ANOVA test was considered statistically significant. Kaplan-Meier estimates were calculated using the GraphPad Prism Software package and a pvalue of 0.05 in a log-rank test indicated a statistically significant difference.
Results
Radiation mitigation in neural stem/progenitor cells in vitro
Passage #2 neurospheres from Nestin-GFP mice, in which most cells were Nestin-GFP + , were used for all in vitro experiments (Figure 1A) . In order to test the self-renewing capacity of the sorted GFP-high, -medium, and -low cells from neurospheres, we performed in vitro limiting dilution assays. Nestin-GFP high cells showed 4.3-fold higher sphere-formation than Nestin-GFP med and 13.5-fold higher sphere-formation than Nestin-GFP low cells (Figure 1B) , thus supporting the neural stem/progenitor phenotype of Nestin-GFP high cells. Irradiation of the neurospheres with 0, 2 or 4 Gy preferentially reduced the size of the Nestin-GFP high cell population (Figure 1C) . This was in line with a previous report on radiation-induced differentiation of neural stem/progenitor cells 13 .
Next, we irradiated neurospheres with 0, 2, or 4 Gy and treated the cells with Compound #5. Compound #5 failed to increase the size of the population of Nestin-GFP high neural stem/progenitor cells (Figure 1D -F) . While Compound #5 did not show any effect on the neurospheres derived from the female newborn pups, it significantly reduced the Nestin-GFP high population of cells derived from the male newborn pups, especially in the 4 Gy treated groups.
Radiation mitigation in neural stem and progenitor cells in vivo
We next considered the possibility that our lead compound targets neural stem/progenitor cells indirectly, which cannot be easily tested in the absence of the correct microenvironment in vitro. To test this, 8 week-old male and female Nestin-GFP mice were irradiated with a dose of 4 Gy to the right brain hemisphere. The radiation treatment plans ensured sparing of the contralateral hemisphere from irradiation, thus allowing for an internal unirradiated control for each individual mouse. Twenty-four hours later the animals were treated with 4 daily injections of Cremophor or compound #5. Tthe brains were harvested, digested and analyzed for the number of Nestin-GFP high stem/progenitor cells and the cells tested for their self-renewing capacity.
Compound #5 significantly increased the number of Nestin-GFP high stem/progenitor cells in female mice (Figure 1G, left panel) . In male mice we observed a similar trend but the effect was not significant (Figure 1H, left panel) .
In in vitro limiting dilution assays we observed a significant increase in sphereforming capacity in cells obtained from female mice treated with compound #5 but not in cells obtained from male mice (Figure 1 G & H, right panel) .
Therefore, all remaining studies were conducted in female mice.
Compound #5 mitigates radiation-induced neuro-inflammation
Six-week old female C3H mice treated with a single fraction of 4 or 10 Gy to the right brain hemisphere (Figure 2A) . Starting wenty-four hours after irradiation, the mice were treated with either Cremophor or Compound #5 for 5 days. The brains were harvested, fixed in formalin, embedded in paraffin and 4 µM sections subjected to immunohistochemistry (IHC). Sections were stained with H&E, or against GFAP (reactive astrocytes marker), IBA1 (activated microglia marker) and Ki67 (proliferation marker) and subjected to an automated image analysis (Figure 2 B-E) .
The slides were scored for positively stained cells in the cortex, corpus callosum, CA1sp, and the dentate gyrus. In the non-irradiated group, Compound #5 did not show significant changes in GFAP, IBA-1, or Ki67 expression. When Compound #5 was combined with radiation it led to a significant reduction in GFAP and IBA1 expression, thus indicating mitigation of radiation-induced neuro-inflammation ( Figure 3A) .
To further confirm the anti-inflammatory effect of compound #5, we collected conditioned media from EOC20 microglia cells twenty-fours exposure after irradiation with 0 or 10 Gy and treatment with DMSO or compound #5 in vitro. IL-6 secretion levels were assessed usiging san ELISA. In line with the well-known pro-inflammatory effect of radiation we observed a significant increase in the secretion of IL-6 in cells treated with 10 Gy. Consistent with an anti-inflammatory effect, Compound #5 significantly reduced IL-6 secretion levels (4 Gy: 2.5-fold, p=0.0297; 10 Gy: 2-fold, p=0.0425) when compared to the corresponding control group (Figure 3B, left) .
Preservation of cognitive function in irradiated mice
Ionizing radiation to the brain has long been known to cause neuroinflammation, which ultimately leads to a decline in cognitive function 14, 15 . Our short-term experiments indicted that Compound #5 mitigated neuroinflammation. Next we sought to test if treatment with compound #5 also translated into improved cognitive function. After total brain irradiation with 10 Gy (Figure 4A ) animals were treated with either Cremophor or Compound #5 (5 mg/kg) for 5 days. One month after irradiation the animals were subjected to unbiased cognitive testing ( Figure 4B) . Novel Object Recognition (NOR) and Object In Place (OIP) was performed to evaluate impairments in the prefrontal and perirhinal cortices and hippocampus regions. This was followed by Fear Conditioning (FC) tasks for studying deficits in motor, sensory and memory function dependent on the hippocampal regions.
Cranial irradiation of 10 Gy demonstrated a significant behavioral deficit on both NOR and OIP tasks compared to control (Cremophor) groups as indicated by impaired preference to novel object ( Figure 4C ) or place (Figure 4D) ; however when combined with Compound #5 the mice showed significantly improved performance in identifying the novel object ( Figure 4C) or place (Figure 4D) .
Furthermore, the discrimination index (DI) between the un-irradiated and the combined treatment groups were statistically insignificant, indicating that Compound #5 had successfully mitigated the radiation effects. In the FC task, the baseline freezing levels were comparable among the three treatment groups. All groups also showed an increased freezing behavior post 3 tone-shock pairings (context fear bars). Baseline freezing levels forty-eight hours post-trainings showed significantly decreased freezing in irradiated mice when compared to the un-irradiated control mice. Administration of Compound #5 to the irradiated mice reduced the cognitive deficits (Figure 4E) . Treatment of the irradiated mice with Compound #5 led to an increased freezing behavior when compared to the irradiated group, indicating preservation of hippocampal function (Figure 4E) .
Effects of Compound #5 on GBM cells in vitro and in vivo
Radiation mitigators or protectors always bear the risk of radiation protection or mitigation not only in normal tissues but also in tumors. To test the effect of Compound #5 on glioblastoma cells in vitro we performed sphere-forming capacity assays using three different patient-derived GBM cells lines, HK-374, HK-157 and HK-382 in the presence (10 µM) or absence of Compound #5 in combination with irradiation at 0 or 4 Gy. The gliomaspheres were treated with DMSO or Compound #5 every other day for 2 weeks at the end of which the number of spheres formed was counted and presented as percentage of spheres formed. In HK-374 GBM cells Compound #5 significantly reduced its selfrenewing capacity with or without irradiation (Figure 5A, left To test if Compound #5 interfered with the effects of tumor irradiation in vivo, 2x10 5 GL261-luciferase mouse glioma cells were intracranially injected in C57BL/6 mice. Seven days after implantation, tumor grafting was confirmed by bioluminescence imaging (BLI), and the tumors were either sham irradiated or irradiated with 10 Gy. Immediately after irradiation, the mice were treated with either Cremophor or Compound #5 (5 mg/kg) sub-cutaneously. The treatment was given on a 5-days on / 2 days-off schedule for 3 weeks. Weights of the mice were recorded everyday until the study end point. Kaplan-Meier survival estimates showed no effects of Compound #5 alone or in combination with radiation ( Figure 5B) . Importantly, Compound #5 did not show any toxicity and did not lead to weight loss (Figure 5C) . Tumor growth was monitored by the bioluminescence imaging of the tumors at Day 7 (pre-treatment) and at Day 23 (days post implantation, Figure 5D ) and indicated no tumor-promoting effects of Compound #5.
Effects of Compound #5 on the Hedgehog pathway in microglia and GBM cells
Recent publications indicated that deregulated developmental pathways play a key role in GBM progression and tumorigenesis by conferring drug resistance to the tumor cells and that inhibition of Hedgehog pathway induced apoptosis in GBM cells [16] [17] [18] . We had previously demonstrated that Compound #5 activates the Hedgehog pathway through binding to the transmembrane domain of (Figure 6A -D) , suggesting that microglia cells are more sensitive to Compound #5 than HK-374 glioma cells.
Discussion
Aside from surgery, radiotherapy is one of the most effective cancer treatments for patients suffering from brain cancer or cancer metastases to brain. However, with 5-year survival rates steadily increasing, more and more patients experience Some experimental approaches, while difficult to translate into the clinic, have shown promising results 20-22 , but approved clinical treatment options for preventing the late sequelae of cerebral radiotherapy are few and are mostly limited to radiation treatment volume reduction 23 or sparing of critical brain structures from irradiation 24 . Previous pharmacological radioprotection studies using e.g. Amifostine have been hindered by the lack blood-brain-barrier penetration of the drugs and the general concern of simultaneous protection of tumor cells 25 .
Few pharmacological treatment attempts have been made to mitigate radiation effects to CNS the after completion of treatment and were mostly limited to corticosteroids, which are routinely used to acutely reduce edema but are not sustainable as a long-term treatment option. So far experimental approaches had limited 26 or no success 27 .
We had previously reported that 1-[(4-Nitrophenyl)sulfonyl]-4phenylpiperazine (compound #5) mitigated the acute intestinal radiation syndrome when given 24 hours or later after a lethal dose of radiation through activation of the hedgehog pathway 7,8 . Motivated by reports in the literature that hedgehog signaling also affects neural stem cells [28] [29] [30] we sought to test if compound #5 would mitigate radiation injury in brain tissues.
When given after total brain irradiation compound #5 increased the number of Nestin-GFP-positive cells and their self-renewal capacity in the brains of female mice while it had no effect on male mice. It is noteworthy that the self- Importantly, compound #5 was well tolerated with no side effects observed and it did not attenuate the effects of radiation on glioma cells in vitro or in vivo, This indicates that compound #5 could be safely administered during or after completion of radiotherapy in patients suffering from glioblastoma, where the presence of residual tumors cells after completion of surgery and radiotherapy is almost always inevitable. An explanation for the differential effects of compound #5 on normal and malignant cells could be that the Hedgehog signaling pathway is utilized in gliomas at a different threshold resulting in differential responses to activators of this pathway. Lastly, the observed effects of compound #5 were not restricted to changes at the cellular level but translated into preservation of cognitive function in the animals.
We conclude, that 1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine or its analogs have the potential to mitigate radiation effects to the normal brain when given during or after radiotherapy and warrant further investigation. 
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